Legend Biotech Corporation (NASDAQ:LEGN) is considered one of the most promising future stocks by Wall Street analysts. RBC Capital raised the price target on LEGN to $77 from $75 on August 12, maintaining an Outperform rating. The company focuses on developing novel therapies for oncology and other indications, operating in the US, China, and other regions. Analysts believe LEGN’s Q2 beat indicates strong demand and successful manufacturing for Carvykti, supporting sustainable growth for the franchise. While LEGN shows potential as an investment, some believe other AI stocks offer greater upside potential and less downside risk.

Read more at Yahoo Finance: RBC Capital Lifts PT on Legend Biotech Corporation (LEGN) to $77 From $75